25 XP   0   0   10

BioLight Life Sciences Ltd
Buy, Hold or Sell?

Let's analyse BioLight Life Sciences Ltd together

PenkeI guess you are interested in BioLight Life Sciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioLight Life Sciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BioLight Life Sciences Ltd

I send you an email if I find something interesting about BioLight Life Sciences Ltd.

Quick analysis of BioLight Life Sciences Ltd (30 sec.)










What can you expect buying and holding a share of BioLight Life Sciences Ltd? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA1,173.28
Expected worth in 1 year
ILA498.05
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
ILA-675.23
Return On Investment
-119.5%

For what price can you sell your share?

Current Price per Share
ILA565.00
Expected price per share
ILA510.60 - ILA679.00
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of BioLight Life Sciences Ltd (5 min.)




Live pricePrice per Share (EOD)

ILA565.00

Intrinsic Value Per Share

ILA-756.02 - ILA996.51

Total Value Per Share

ILA417.26 - ILA2,169.79

2. Growth of BioLight Life Sciences Ltd (5 min.)




Is BioLight Life Sciences Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$13.9m$15.9m-$2m-14.4%

How much money is BioLight Life Sciences Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$2m$99.1k-$2.1m-104.9%
Net Profit Margin-12,455.6%12,733.3%--

How much money comes from the company's main activities?

3. Financial Health of BioLight Life Sciences Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of BioLight Life Sciences Ltd? (5 min.)

Welcome investor! BioLight Life Sciences Ltd's management wants to use your money to grow the business. In return you get a share of BioLight Life Sciences Ltd.

What can you expect buying and holding a share of BioLight Life Sciences Ltd?

First you should know what it really means to hold a share of BioLight Life Sciences Ltd. And how you can make/lose money.

Speculation

The Price per Share of BioLight Life Sciences Ltd is ILA565.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BioLight Life Sciences Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BioLight Life Sciences Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA1,173.28. Based on the TTM, the Book Value Change Per Share is ILA-168.81 per quarter. Based on the YOY, the Book Value Change Per Share is ILA28.63 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BioLight Life Sciences Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps-0.45-0.1%-0.45-0.1%0.020.0%0.360.1%-0.39-0.1%
Usd Book Value Change Per Share-0.44-0.1%-0.44-0.1%0.070.0%0.520.1%0.090.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.44-0.1%-0.44-0.1%0.070.0%0.520.1%0.090.0%
Usd Price Per Share1.77-1.77-3.00-2.46-5.10-
Price to Earnings Ratio-3.97--3.97-138.25-25.87-9.50-
Price-to-Total Gains Ratio-4.03--4.03-40.31-5.71-5.34-
Price to Book Ratio0.58-0.58-0.86-0.67-3.60-
Price-to-Total Gains Ratio-4.03--4.03-40.31-5.71-5.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.46674
Number of shares681
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.440.52
Usd Total Gains Per Share-0.440.52
Gains per Quarter (681 shares)-298.43352.79
Gains per Year (681 shares)-1,193.721,411.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1194-1204014111401
20-2387-2398028222812
30-3581-3592042344223
40-4775-4786056455634
50-5969-5980070567045
60-7162-7174084678456
70-8356-8368098789867
80-9550-956201128911278
90-10743-1075601270112689
100-11937-1195001411214100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.08.00.020.0%3.08.05.018.8%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%8.08.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.016.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%8.08.00.050.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of BioLight Life Sciences Ltd

About BioLight Life Sciences Ltd

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.

Fundamental data was last updated by Penke on 2023-09-29 02:32:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of BioLight Life Sciences Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BioLight Life Sciences Ltd earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -12,455.6% means that -124.56 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioLight Life Sciences Ltd:

  • The MRQ is -12,455.6%. The company is making a huge loss. -2
  • The TTM is -12,455.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-12,455.6%TTM-12,455.6%0.0%
TTM-12,455.6%YOY12,733.3%-25,188.9%
TTM-12,455.6%5Y-9,071.2%-3,384.4%
5Y-9,071.2%10Y-7,462.9%-1,608.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12,455.6%-175.6%-12,280.0%
TTM-12,455.6%-215.7%-12,239.9%
YOY12,733.3%-317.1%+13,050.4%
5Y-9,071.2%-498.6%-8,572.6%
10Y-7,462.9%-627.2%-6,835.7%
1.1.2. Return on Assets

Shows how efficient BioLight Life Sciences Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • -13.8% Return on Assets means that BioLight Life Sciences Ltd generated -0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioLight Life Sciences Ltd:

  • The MRQ is -13.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.8%TTM-13.8%0.0%
TTM-13.8%YOY0.6%-14.4%
TTM-13.8%5Y4.4%-18.1%
5Y4.4%10Y-25.2%+29.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.8%-12.0%-1.8%
TTM-13.8%-11.7%-2.1%
YOY0.6%-10.7%+11.3%
5Y4.4%-13.6%+18.0%
10Y-25.2%-15.2%-10.0%
1.1.3. Return on Equity

Shows how efficient BioLight Life Sciences Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • -14.8% Return on Equity means BioLight Life Sciences Ltd generated -0.15 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioLight Life Sciences Ltd:

  • The MRQ is -14.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.8%TTM-14.8%0.0%
TTM-14.8%YOY0.6%-15.4%
TTM-14.8%5Y4.9%-19.6%
5Y4.9%10Y-74.7%+79.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.8%-14.7%-0.1%
TTM-14.8%-14.3%-0.5%
YOY0.6%-13.0%+13.6%
5Y4.9%-18.7%+23.6%
10Y-74.7%-19.6%-55.1%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of BioLight Life Sciences Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BioLight Life Sciences Ltd is operating .

  • Measures how much profit BioLight Life Sciences Ltd makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioLight Life Sciences Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-353,433.3%+353,433.3%
TTM-5Y-78,844.8%+78,844.8%
5Y-78,844.8%10Y-43,757.9%-35,086.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--334.9%+334.9%
TTM--209.9%+209.9%
YOY-353,433.3%-320.9%-353,112.4%
5Y-78,844.8%-476.3%-78,368.5%
10Y-43,757.9%-566.2%-43,191.7%
1.2.2. Operating Ratio

Measures how efficient BioLight Life Sciences Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 164.84 means that the operating costs are 164.84 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of BioLight Life Sciences Ltd:

  • The MRQ is 164.841. The company is inefficient in keeping operating costs low. -1
  • The TTM is 164.841. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ164.841TTM164.8410.000
TTM164.841YOY3,535.333-3,370.492
TTM164.8415Y820.310-655.469
5Y820.31010Y454.409+365.900
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ164.8412.987+161.854
TTM164.8413.255+161.586
YOY3,535.3334.049+3,531.284
5Y820.3105.926+814.384
10Y454.4097.574+446.835
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of BioLight Life Sciences Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if BioLight Life Sciences Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.11 means the company has 7.11 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of BioLight Life Sciences Ltd:

  • The MRQ is 7.107. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.107. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.107TTM7.1070.000
TTM7.107YOY15.379-8.272
TTM7.1075Y13.286-6.179
5Y13.28610Y9.079+4.207
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1074.061+3.046
TTM7.1074.617+2.490
YOY15.3795.803+9.576
5Y13.2866.252+7.034
10Y9.0796.594+2.485
1.3.2. Quick Ratio

Measures if BioLight Life Sciences Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 1.18 means the company can pay off 1.18 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioLight Life Sciences Ltd:

  • The MRQ is 1.178. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.178. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.178TTM1.1780.000
TTM1.178YOY0.039+1.138
TTM1.1785Y2.143-0.965
5Y2.14310Y1.279+0.864
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1783.799-2.621
TTM1.1784.383-3.205
YOY0.0395.513-5.474
5Y2.1436.019-3.876
10Y1.2796.319-5.040
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of BioLight Life Sciences Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BioLight Life Sciences Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BioLight Life Sciences Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that BioLight Life Sciences Ltd assets are financed with 5.8% credit (debt) and the remaining percentage (100% - 5.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioLight Life Sciences Ltd:

  • The MRQ is 0.058. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.058. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.058TTM0.0580.000
TTM0.058YOY0.043+0.015
TTM0.0585Y0.081-0.022
5Y0.08110Y0.259-0.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0580.325-0.267
TTM0.0580.321-0.263
YOY0.0430.262-0.219
5Y0.0810.373-0.292
10Y0.2590.388-0.129
1.4.2. Debt to Equity Ratio

Measures if BioLight Life Sciences Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.2% means that company has 0.06 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioLight Life Sciences Ltd:

  • The MRQ is 0.062. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.062. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.062TTM0.0620.000
TTM0.062YOY0.045+0.017
TTM0.0625Y0.088-0.025
5Y0.08810Y0.688-0.601
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0620.366-0.304
TTM0.0620.377-0.315
YOY0.0450.302-0.257
5Y0.0880.436-0.348
10Y0.6880.480+0.208
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of BioLight Life Sciences Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings BioLight Life Sciences Ltd generates.

  • Above 15 is considered overpriced but always compare BioLight Life Sciences Ltd to the Biotechnology industry mean.
  • A PE ratio of -3.97 means the investor is paying -3.97 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioLight Life Sciences Ltd:

  • The EOD is -3.295. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.966. Based on the earnings, the company is expensive. -2
  • The TTM is -3.966. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.295MRQ-3.966+0.671
MRQ-3.966TTM-3.9660.000
TTM-3.966YOY138.246-142.211
TTM-3.9665Y25.869-29.835
5Y25.86910Y9.499+16.370
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.295-1.915-1.380
MRQ-3.966-2.424-1.542
TTM-3.966-2.620-1.346
YOY138.246-5.285+143.531
5Y25.869-6.156+32.025
10Y9.499-6.387+15.886
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioLight Life Sciences Ltd:

  • The EOD is -2.683. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.229. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.229. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.683MRQ-3.229+0.546
MRQ-3.229TTM-3.2290.000
TTM-3.229YOY-4.958+1.729
TTM-3.2295Y-3.192-0.036
5Y-3.19210Y-4.207+1.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.683-2.614-0.069
MRQ-3.229-3.268+0.039
TTM-3.229-3.687+0.458
YOY-4.958-7.093+2.135
5Y-3.192-8.275+5.083
10Y-4.207-8.536+4.329
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BioLight Life Sciences Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.58 means the investor is paying 0.58 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of BioLight Life Sciences Ltd:

  • The EOD is 0.482. Based on the equity, the company is cheap. +2
  • The MRQ is 0.580. Based on the equity, the company is cheap. +2
  • The TTM is 0.580. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.482MRQ0.580-0.098
MRQ0.580TTM0.5800.000
TTM0.580YOY0.860-0.280
TTM0.5805Y0.670-0.091
5Y0.67010Y3.599-2.929
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4821.655-1.173
MRQ0.5801.970-1.390
TTM0.5802.140-1.560
YOY0.8603.333-2.473
5Y0.6703.580-2.910
10Y3.5994.055-0.456
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BioLight Life Sciences Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---168.807-168.8070%28.626-690%199.557-185%35.737-572%
Book Value Per Share--1173.2781173.2780%1342.084-13%1403.593-16%962.598+22%
Current Ratio--7.1077.1070%15.379-54%13.286-47%9.079-22%
Debt To Asset Ratio--0.0580.0580%0.043+36%0.081-28%0.259-78%
Debt To Equity Ratio--0.0620.0620%0.045+38%0.088-29%0.688-91%
Dividend Per Share----0%-0%-0%-0%
Eps---171.473-171.4730%8.347-2154%139.621-223%-149.326-13%
Free Cash Flow Per Share---210.610-210.6100%-232.768+11%-312.982+49%-442.274+110%
Free Cash Flow To Equity Per Share---210.610-210.6100%-212.773+1%-111.808-47%-86.342-59%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--996.514--------
Intrinsic Value_10Y_min---756.015--------
Intrinsic Value_1Y_max---171.887--------
Intrinsic Value_1Y_min---255.767--------
Intrinsic Value_3Y_max---309.350--------
Intrinsic Value_3Y_min---617.120--------
Intrinsic Value_5Y_max---197.133--------
Intrinsic Value_5Y_min---809.821--------
Market Cap2585575600.000-20%3111843200.0003111843200.0000%5280980960.000-41%4330953536.000-28%8986606172.780-65%
Net Profit Margin---124.556-124.5560%127.333-198%-90.712-27%-74.629-40%
Operating Margin----0%-3534.3330%-788.4480%-437.5790%
Operating Ratio--164.841164.8410%3535.333-95%820.310-80%454.409-64%
Pb Ratio0.482-20%0.5800.5800%0.860-33%0.670-14%3.599-84%
Pe Ratio-3.295+17%-3.966-3.9660%138.246-103%25.869-115%9.499-142%
Price Per Share565.000-20%680.000680.0000%1154.000-41%946.400-28%1963.753-65%
Price To Free Cash Flow Ratio-2.683+17%-3.229-3.2290%-4.958+54%-3.192-1%-4.207+30%
Price To Total Gains Ratio-3.347+17%-4.028-4.0280%40.313-110%5.712-171%5.339-175%
Quick Ratio--1.1781.1780%0.039+2893%2.143-45%1.279-8%
Return On Assets---0.138-0.1380%0.006-2412%0.044-415%-0.252+83%
Return On Equity---0.148-0.1480%0.006-2445%0.049-402%-0.747+406%
Total Gains Per Share---168.807-168.8070%28.626-690%199.557-185%35.737-572%
Usd Book Value--13938443.20013938443.2000%15943853.200-13%16674575.280-16%11435587.680+22%
Usd Book Value Change Per Share---0.438-0.4380%0.074-690%0.518-185%0.093-572%
Usd Book Value Per Share--3.0463.0460%3.484-13%3.644-16%2.499+22%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.445-0.4450%0.022-2154%0.362-223%-0.388-13%
Usd Free Cash Flow---2502024.800-2502024.8000%-2765259.200+11%-3718198.880+49%-5254174.200+110%
Usd Free Cash Flow Per Share---0.547-0.5470%-0.604+11%-0.813+49%-1.148+110%
Usd Free Cash Flow To Equity Per Share---0.547-0.5470%-0.552+1%-0.290-47%-0.224-59%
Usd Market Cap6712154.258-20%8078344.9478078344.9470%13709426.572-41%11243155.379-28%23329229.625-65%
Usd Price Per Share1.467-20%1.7651.7650%2.996-41%2.457-28%5.098-65%
Usd Profit---2037081.200-2037081.2000%99167.200-2154%1658688.240-223%-1773976.600-13%
Usd Revenue--16354.80016354.8000%778.800+2000%211885.520-92%254797.400-94%
Usd Total Gains Per Share---0.438-0.4380%0.074-690%0.518-185%0.093-572%
 EOD+3 -5MRQTTM+0 -0YOY+11 -215Y+10 -2210Y+14 -18

3.2. Fundamental Score

Let's check the fundamental score of BioLight Life Sciences Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.295
Price to Book Ratio (EOD)Between0-10.482
Net Profit Margin (MRQ)Greater than0-124.556
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.178
Current Ratio (MRQ)Greater than17.107
Debt to Asset Ratio (MRQ)Less than10.058
Debt to Equity Ratio (MRQ)Less than10.062
Return on Equity (MRQ)Greater than0.15-0.148
Return on Assets (MRQ)Greater than0.05-0.138
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of BioLight Life Sciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.941
Ma 20Greater thanMa 50585.370
Ma 50Greater thanMa 100621.300
Ma 100Greater thanMa 200617.519
OpenGreater thanClose560.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in ILS. All numbers in thousands.

Summary
Total Assets57,011
Total Liabilities3,319
Total Stockholder Equity53,168
 As reported
Total Liabilities 3,319
Total Stockholder Equity+ 53,168
Total Assets = 57,011

Assets

Total Assets57,011
Total Current Assets18,024
Long-term Assets18,024
Total Current Assets
Cash And Cash Equivalents 13,392
Short-term Investments 2,987
Total Current Assets  (as reported)18,024
Total Current Assets  (calculated)16,379
+/- 1,645
Long-term Assets
Long-term Assets  (as reported)38,987
Long-term Assets  (calculated)0
+/- 38,987

Liabilities & Shareholders' Equity

Total Current Liabilities2,536
Long-term Liabilities783
Total Stockholder Equity53,168
Total Current Liabilities
Accounts payable 301
Total Current Liabilities  (as reported)2,536
Total Current Liabilities  (calculated)301
+/- 2,235
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt527
Long-term Liabilities  (as reported)783
Long-term Liabilities  (calculated)527
+/- 256
Total Stockholder Equity
Total Stockholder Equity (as reported)53,168
Total Stockholder Equity (calculated)0
+/- 53,168
Other
Capital Stock11,443
Common Stock Shares Outstanding 4,576
Net Invested Capital 53,168
Net Working Capital 15,488



Balance Sheet

Currency in ILS. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312006-12-312005-12-31
> Total Assets 
20,390
48,163
22,489
10,139
29,632
41,891
34,332
40,434
63,271
35,313
24,763
90,282
74,951
64,829
64,171
57,011
57,01164,17164,82974,95190,28224,76335,31363,27140,43434,33241,89129,63210,13922,48948,16320,390
   > Total Current Assets 
0
0
0
0
0
0
21,009
32,432
53,439
30,031
19,860
62,513
40,712
51,460
34,004
18,024
18,02434,00451,46040,71262,51319,86030,03153,43932,43221,009000000
       Cash And Cash Equivalents 
2,310
5,072
9,624
5,413
4,751
28,497
17,716
22,196
50,697
25,474
15,355
43,058
35,346
29,988
33,467
13,392
13,39233,46729,98835,34643,05815,35525,47450,69722,19617,71628,4974,7515,4139,6245,0722,310
       Short-term Investments 
17,333
38,750
10,996
2,158
7,029
610
185
6,408
385
417
412
387
4,604
19,961
0
2,987
2,987019,9614,6043874124173856,4081856107,0292,15810,99638,75017,333
       Net Receivables 
130
126
445
308
237
959
1,584
813
866
1,669
512
725
565
92
87
0
087925657255121,6698668131,584959237308445126130
       Inventory 
0
0
0
0
0
583
1,055
976
991
2,494
2,846
0
0
0
0
0
000002,8462,4949919761,05558300000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
5,282
4,903
27,769
34,239
13,369
30,167
38,987
38,98730,16713,36934,23927,7694,9035,282000000000
       Property Plant Equipment 
0
176
1,095
1,790
1,663
947
911
819
743
1,287
922
304
714
3,163
3,257
0
03,2573,1637143049221,2877438199119471,6631,7901,0951760
       Goodwill 
0
0
0
0
0
0
4,678
3,873
3,873
3,873
3,873
3,873
3,873
112
112
0
01121123,8733,8733,8733,8733,8733,8734,678000000
       Long Term Investments 
0
0
0
0
0
0
0
0
79
0
0
20,006
0
0
0
0
000020,006007900000000
       Intangible Assets 
263
994
0
0
0
0
12,307
7,106
2,996
37
37
37
37
37
37
0
03737373737372,9967,10612,3070000994263
       Other Assets 
0
40
90
100
52
38
105
77
2,141
85
71
3,549
1,003
0
946
0
094601,0033,54971852,14177105385210090400
> Total Liabilities 
2,689
40,154
9,182
7,417
6,085
4,553
12,223
14,696
16,210
18,903
16,732
12,486
6,804
4,722
2,754
3,319
3,3192,7544,7226,80412,48616,73218,90316,21014,69612,2234,5536,0857,4179,18240,1542,689
   > Total Current Liabilities 
1,862
2,312
3,645
3,553
3,566
1,874
4,898
6,552
6,605
6,988
7,259
5,021
3,571
2,561
2,211
2,536
2,5362,2112,5613,5715,0217,2596,9886,6056,5524,8981,8743,5663,5533,6452,3121,862
       Accounts payable 
74
331
550
639
391
209
1,365
943
873
2,776
737
1,386
221
580
146
301
3011465802211,3867372,7768739431,36520939163955033174
       Other Current Liabilities 
1,787
1,980
3,095
2,914
3,175
1,665
3,533
5,609
859
794
837
211
161
1,522
0
0
001,5221612118377948595,6093,5331,6653,1752,9143,0951,9801,787
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
11,915
9,473
7,465
3,233
2,161
543
783
7835432,1613,2337,4659,47311,915000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
450
929
443
527
527443929450000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
11,915
9,273
5,177
2,225
0
0
0
0002,2255,1779,27311,915000000000
> Total Stockholder Equity
17,701
8,008
4,964
0
22,882
38,285
12,573
28,403
34,644
10,841
6,100
82,331
68,863
59,217
60,702
53,168
53,16860,70259,21768,86382,3316,10010,84134,64428,40312,57338,28522,88204,9648,00817,701
   Common Stock
289
331
701
917
1,765
3,423
3,423
5,215
6,519
6,519
9,088
11,359
11,359
11,359
11,401
0
011,40111,35911,35911,3599,0886,5196,5195,2153,4233,4231,765917701331289
   Retained Earnings Total Equity0000000000000000
   Accumulated Other Comprehensive Income 0000000000000000
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
14,217
20,595
18,591
10,040
6,390
6,166
5,289
8,856
9,719
0
09,7198,8565,2896,1666,39010,04018,59120,59514,217000000



Balance Sheet

Currency in ILS. All numbers in thousands.




Cash Flow

Currency in ILS. All numbers in thousands.




Income Statement

Currency in ILS. All numbers in thousands.